Autres langues Equillium, Inc.

Actions

EQ

US29446K1060

Temps Différé Nasdaq Autres places de cotation 15:35:51 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,72 ^USD	+0,58%		+4,24%	+137,90%

02/04	EQUILLIUM, INC. : HC Wainwright réitère son opinion positive sur le titre	ZM
01/04	Equillium annonce des résultats positifs pour la partie de type B de l'étude de phase 1B EQUALISE sur l'itolizumab dans le lupus néphrétique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/04
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis	01/04
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	01/04
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26/03
Equillium Swings to Q4 Loss As Revenue Falls	25/03
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	25/03
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	25/03
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights	25/03
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25/03
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference	22/03
EQUILLIUM : 2024 INDUCEMENT PLAN - Form 8-K	08/03
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 and EQ102 in Development for Alopecia Areata and Celiac Disease	22/12
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	21/12
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	21/12
EQ Bank Card launches in Québec as Carte Banque EQ	20/11
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology	13/11
Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology	13/11
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	08/11
Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Equillium, Inc.

Actions

EQ

US29446K1060

Autres langues

Filtres